Common Men's Health Issues in Men Over 65
The most common health issues in men over 65 are benign prostatic hyperplasia (BPH) causing lower urinary tract symptoms (LUTS), hypertension, and prostate cancer, with BPH affecting up to 80% of men by age 80. 1
Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms
BPH is nearly ubiquitous in aging men, reaching 60% prevalence by age 60 and 80% by age 80. 1 This condition leads to bothersome urinary symptoms that significantly impact quality of life through:
- Storage symptoms: Frequency, urgency, nocturia (getting up 2+ times per night)
- Voiding symptoms: Weak stream, hesitancy, incomplete emptying, straining
The prevalence of moderate-to-severe LUTS rises to nearly 50% by age 80, with acute urinary retention increasing from 6.8 episodes per 1,000 patient-years overall to 34.7 episodes in men aged 70 and older. 1 An estimated 90% of men between 45-80 years experience some type of LUTS. 1
Clinical Approach to BPH/LUTS
Initial evaluation must include:
- International Prostate Symptom Score (IPSS) to quantify severity and bother
- Urinalysis to rule out infection or hematuria
- Digital rectal examination to assess prostate size
- Post-void residual measurement if retention suspected 1
First-line management starts with alpha-blockers (such as tamsulosin, alfuzosin) for immediate symptom relief. 1 For prostates >30cc, adding a 5-alpha reductase inhibitor (5ARI like finasteride or dutasteride) provides long-term prostate size reduction and prevents disease progression. 1
Cardiovascular Disease
Hypertension ranks as the first or second most prevalent condition across all age categories in men over 50, followed closely by coronary artery disease (CAD). 2 In the Medicare-eligible population:
- 53-56% have hypertension 3
- CAD prevalence increases dramatically with age
- 67% of hypertensives are ≥65 years old, with 24% ≥80 years 4
- 73% with ischemic heart disease are ≥65 years, with 29% ≥80 years 4
Cardiovascular conditions comprise a significant portion of the disease burden, with arrhythmias also ranking among the top 10 conditions. 2
Prostate Cancer
Prostate cancer is the most common cancer in older men (excluding skin cancer), with men having approximately a 1 in 6 lifetime chance of diagnosis. 5 Key epidemiologic facts:
- Median age at diagnosis is 71 years 6
- More than 70% of cases occur in men >65 years 6
- Only 2 in 10 prostate cancer deaths occur in men aged 65-74 years, while 7 in 10 occur in men ≥75 years 5
- African-American men have substantially higher risk and more aggressive disease 5, 7
Screening Considerations
For men over 65 with at least 10 years life expectancy, shared decision-making about PSA screening is essential. 7 The discussion must cover:
- PSA testing increases cancer detection but also identifies slow-growing cancers that may never cause harm
- Treatment causes significant side effects: erectile dysfunction, urinary incontinence, bowel dysfunction
- Many prostate cancers grow slowly enough that men die of other causes first 5
Men over 75 or with <10 years life expectancy should not undergo routine screening. 8, 7, 9
Other Prevalent Conditions
Additional common conditions in men over 65 include:
- Diabetes mellitus: 26% prevalence in men >50, though decreases with advancing age 3, 2
- Enlarged prostate: Ranks fourth across age categories 2
- Osteoarthritis: 26% in men, increases with age 3
- Depression: 31% prevalence 3
- Atrial fibrillation: 42% of patients are ≥80 years 4
- Congestive heart failure: 18% prevalence, 40% of patients ≥80 years 3, 4
Common Pitfalls
- Assuming all LUTS are due to BPH: Must rule out bladder dysfunction, neurologic causes, and malignancy
- Overtreating indolent prostate cancer: Many screen-detected cancers never require treatment
- Underestimating polypharmacy risks: Men over 65 average multiple chronic conditions requiring careful medication management 10
- Ignoring quality of life impact: Symptom severity matters less than how much it bothers the patient 1, 11
The key to managing health issues in men over 65 is recognizing that BPH/LUTS, cardiovascular disease, and prostate cancer dominate the landscape, with treatment decisions heavily influenced by life expectancy, comorbidities, and patient values regarding quality of life versus treatment burden.